A5077671918- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Blood groups and transfusion
- Hematopoietic Stem Cell Transplantation
- Autoimmune and Inflammatory Disorders Research
- Platelet Disorders and Treatments
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Viral-associated cancers and disorders
- Parvovirus B19 Infection Studies
- Erythropoietin and Anemia Treatment
- Hemophilia Treatment and Research
- Venous Thromboembolism Diagnosis and Management
- T-cell and B-cell Immunology
- Atrial Fibrillation Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Hematological disorders and diagnostics
- Blood transfusion and management
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Animal Ecology and Behavior Studies
Florida Cancer Specialists & Research Institute
2020-2023
Johns Hopkins University
2015-2021
Johns Hopkins Medicine
2015-2021
Florida Cancer Care
2021
Sidney Kimmel Comprehensive Cancer Center
2017-2020
Vanderbilt-Ingram Cancer Center
2020
Immune Regulation (United Kingdom)
2019
Johns Hopkins Hospital
2019
Johns Hopkins Bayview Medical Center
2015-2019
Flushing Hospital Medical Center
2019
Immune checkpoint inhibitors (ICIs) are the standard of care for treatment several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks toxicity, specifically immune-related adverse events (irAEs). There is a need clear, effective guidelines management irAEs during ICI treatment, motivating Society Immunotherapy Cancer (SITC) to convene an expert panel develop practice guideline. The discussed recognition and single...
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated effect of age on NMA haplo-BMT outcomes patients 50 to 75 years. Patients and Methods A retrospective analysis was performed 271 consecutive with hematologic malignancies, years, who received NMA, T-cell–replete high-dose post-transplantation cyclophosphamide. Results The median 61 115 (42%) 59, 129 (48%) 60 69, 27 (10%)...
To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) Sézary syndrome (SS).
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) a rare erythrodermic leukemic CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy often necessary for treatment advanced-stage disease. Systemic options have evolved in recent years approval novel agents such as romidepsin, brentuximab vedotin, mogamulizumab. These...
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs). Methods to obtain real-time multidisciplinary input for irAEs that require subspecialist care are unknown. This study aimed determine whether a virtual toxicity (IR-tox) team of oncology and medicine subspecialists would be feasible implement, used by providers, identify patients whom is sought.Patients treated with ICIs referred the IR-tox in August 2017 through March 2018 were identified. Feasibility was...
Abstract Background. Histoplasmosis-associated hemophagocytic lymphohistiocytosis (HLH) is a relatively rare disorder for which data are limited regarding optimal treatment and clinical outcomes in adults. We describe the features, treatment, of patients with histoplasmosis-associated HLH at our institution. Methods. performed retrospective chart review all inpatients Parkland Hospital diagnosed associated Histoplasma capsulatum from 2003 to 2013. Results. Eleven cases over this time period...
Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell predominantly extranodal most these nasal type, often localized to the upper aerodigestive tract. Because (ENKL) malignancies, randomized trials comparing different regimens have not been conducted date standard therapy has yet established for patients. These NCCN Guidelines Insights discuss recommendations diagnosis management patients with ENKL as outlined in T-Cell Lymphomas.
We report a patient with high-titer factor VIII inhibitor refractory to immunosuppression. He initially presented myocardial infarction requiring percutaneous coronary intervention (PCI) bare metal stent placement. Despite Feiba prophylaxis, inadequate hemostasis prompted premature discontinuation of dual antiplatelet therapy (DAPT). Fifteen weeks later, the left anterior descending artery in-stent restenosis. This case examines Key Clinical Question how manage restenosis in acquired...
With post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, nonmyeloablative HLA-haploidentical (NMA haplo) and HLA-matched blood or marrow transplantation (BMT) have comparable outcomes. Early discontinuation of immunosuppression may reduce the risk relapse improve immune reconstitution, but increase GVHD. We conducted a prospective trial NMA haplo BMT for patients with hematologic malignancies (median age, 61 years), evaluating safety early...
Outcomes of nonmyeloablative (NMA), HLA-haploidentical (haplo), related-donor allogeneic blood or marrow transplantation (allo-BMT) with high-dose post-transplantation cyclophosphamide (PTCy) appear to be similar those using HLA-matched donors. Thus, it may possible prioritize donor factors other than HLA matching that could enhance antitumor activity. The Fc receptor polymorphism FCGR3A-158VV confer greater sensitivity rituximab FCGR3A-158FF. In a prospective phase II study NMA, allo-BMT...
Hemophagocytic lymphohistiocytosis (HLH) is a highly fatal, hyperinflammatory syndrome in adults triggered by an underlying illness most cases. As such, suspicion of HLH dictates further investigation to identify the trigger and determine treatment. clinically challenging due diverse presentations triggers, provider unfamiliarity, bleeding complications. Clinically, we observed diagnostic error from incorrect testing cognitive biases (interleukin-2 confused with soluble interleukin-2...
Prior to the introduction of rituximab, primary mediastinal B-cell lymphoma (PMBCL) had high rates treatment failure with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), prompting use consolidative radiation or more intensive chemotherapy regimens. Cure improved dramatically but was still commonly employed R-CHOP. We performed a retrospective review patients treated R-CHOP alone without for PMBCL. Of 43 PMBCL, 16 received alone. High-risk factors included 56% bulky...
Allogeneic blood or marrow transplantation (alloBMT) may lead to long-term disease control in patients with multiple myeloma (MM). However, historically, the use of alloBMT MM has been limited by its high nonrelapse mortality (NRM) rates, primarily from graft-versus-host (GVHD). We previously demonstrated that post-transplantation cyclophosphamide (PTCy) decreases toxicities both acute and chronic GVHD after alloBMT. Here, we examine impact PTCy undergoing at Johns Hopkins Hospital. From...
Allogeneic blood or marrow transplantation (allo-BMT) remains the only treatment for chronic lymphocytic leukemia (CLL) with curative potential. Although post-transplantation cyclophosphamide (PTCy) reduces allo-BMT toxicity by decreasing risk of graft-versus-host disease (GVHD), its effect on CLL outcomes is unknown. We studied 64 consecutive patients who underwent nonmyeloablative (NMA) haploidentical at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. In this cohort, 4-year...
Background: An antithrombotic stewardship program was implemented to reduce IV DTI use and increase fondaparinux direct oral anticoagulant (DOAC) for suspected or confirmed Heparin-induced thrombocytopenia (HIT). Objectives: This study evaluated the impact of an on utilization in patients with HIT. Methods: A retrospective analysis adults receiving DTIs from July 2016 2017 (pre-stewardship) October 2019 (post-stewardship) conducted. Results: The median duration administration not...